Orna Therapeutics, Inc.
Orna Therapeutics is dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA®) therapeutics to unlock the potential of RNA medicine to treat diseases anywhere in the body. Their technology focuses on engineered circular RNA and lipid nanoparticle delivery systems, aiming to transform patient care across oncology, autoimmune, infectious, and genetic diseases. The company emphasizes innovation, collaboration, and a commitment to advancing RNA therapeutics to improve lives.
Industries
Nr. of Employees
medium (51-250)
Orna Therapeutics, Inc.
Products
Circular RNA therapeutic platform with LNP delivery
An integrated platform pairing engineered circular RNA constructs with lipid nanoparticle delivery systems to enable vaccines, in vivo CAR therapies, and RNA editing approaches targeting extra-hepatic tissues.
In vivo panCAR therapeutic programs (CD19 and BCMA targets)
Program-level assets intended to induce CAR expression in vivo to deplete target B cells (CD19) for autoimmune disease and to target BCMA for multiple myeloma; programs are being advanced toward clinical studies.
Circular RNA therapeutic platform with LNP delivery
An integrated platform pairing engineered circular RNA constructs with lipid nanoparticle delivery systems to enable vaccines, in vivo CAR therapies, and RNA editing approaches targeting extra-hepatic tissues.
In vivo panCAR therapeutic programs (CD19 and BCMA targets)
Program-level assets intended to induce CAR expression in vivo to deplete target B cells (CD19) for autoimmune disease and to target BCMA for multiple myeloma; programs are being advanced toward clinical studies.
Services
Collaborative drug development and pharma partnerships
Strategic collaborations with pharmaceutical companies for co-development of vaccines, infectious disease therapeutics, oncology and genetic disease programs.
Preclinical development and translational research
Design and execution of preclinical studies including biodistribution, pharmacodynamic assessments, and efficacy models in humanized mice and non-human primates to support clinical translation.
Collaborative drug development and pharma partnerships
Strategic collaborations with pharmaceutical companies for co-development of vaccines, infectious disease therapeutics, oncology and genetic disease programs.
Preclinical development and translational research
Design and execution of preclinical studies including biodistribution, pharmacodynamic assessments, and efficacy models in humanized mice and non-human primates to support clinical translation.
Expertise Areas
- Circular RNA therapeutics
- LNP delivery and formulation
- In vivo cell engineering (in vivo CAR platforms)
- Preclinical pharmacology and animal models (humanized mice, NHPs)
Key Technologies
- Circular RNA constructs
- Lipid nanoparticle (LNP) formulation
- In vivo CAR expression platforms
- RNA editing platforms